Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons,

Slides:

Advertisements

Similar presentations

Mary Ellen Turner MD, MPH Vice-President

Advertisements

“The GMC aims to encourage a culture where the patient and public perspective is sought and recognised across the spectrum of medical education” Paragraph.

Introduction to Drug Information Services Ch.#1. An introductory course to teach the students basic principles of DI retrieval. Designed to help students.

Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.

IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.

Schermerhorn- Chapter 61 Management, 6e Schermerhorn Prepared by Cheryl Wyrick California State Polytechnic University Pomona John Wiley & Sons, Inc.

International Regulatory Capacity Building Global Curriculum Project.

Copyright 2004 John Wiley & Sons, Inc Information Technology: Strategic Decision Making For Managers Henry C. Lucas Jr. John Wiley & Sons, Inc Dinesh.

Chapter Nine Establishing a Thriving Career Development Program Donald A. Schutt, Jr. Career Counseling: Foundations, Perspectives, and Applications edited.

IPhVWP Polish Presidency, Warsaw October 6 th 2011 Almath Spooner Irish Medicines Board Monitoring the outcome of risk minimisation activities.

 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.

Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

Organization of the US Health Services System

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

Cap.org v. FNL FDA: Challenges to Protecting Public Health – Pathology’s Perspective Roger D. Klein, M.D., JD, F.C.A.P. March 7, 2013 Advocacy.

A. Short term problems / considerations b. Long term mission View of human subjects protection system: SACHRP July 2008 Elizabeth Bankert.

Pharmacovigilance Programme of India

The Accelerating Pace of Medical Development and Challenges in Evaluating Benefit and Risk Alasdair Breckenridge Medicines and Healthcare products Regulatory.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

Chapter 2 Standards for Electronic Health Records McGraw-Hill/Irwin Copyright © 2009 by The McGraw-Hill Companies, Inc. All Rights Reserved.

Risk Assessments: Patient Safety and Innovation Innovation Discussion 02 July 2013.

Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.

Using the Balanced Scorecard Approach (NeLH- Health Management) Using the Balanced Scorecard Approach Based on the management briefing by Shaunagh Robertson.

Drug Transfer Into Breast Milk and Interpretation of Data Lawrence J. Lesko Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation.

Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.

+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.

The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:

Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.

1 Evaluating & Applying What Works Best Leaders’ Project Policy Forum Kathy Buto, VP Health Policy April 24, 2008.

A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)

Integrating Compliance with Business: Developing and Implementing the Tysabri Risk Map Reintroduction of a Breakthrough Medical Product November 09, 2006.

Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.

Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.

2 - 1 Introduction to US Health Care Text by Dennis D. Pointer, Stephen J. Williams, Stephen L. Isaacs & James R. Knickman with Tracy Barr PowerPoints.

 To get better and go home as soon as possible.  To be satisfied with the service provided.  To be treated with dignity and their privacy respected.

AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)

2 “The label is the most important product that a company’s research arm produces…” Essence of Licensure Conveys the Use of the Product Describes Efficacy.

Limmer, First Responder: A Skills Approach, 7 th ed. © 2007 by Pearson Education, Inc. Upper Saddle River, NJ Chapter 1 Introduction to the EMS System.

Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Agencies of the Executive Branch Decisions made by any agency of the Executive Branch are considered an executive order and have the power of LAW!!!

European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.

Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.

Introduction to US Health Care Text by Dennis D. Pointer, Stephen J. Williams, Stephen L. Isaacs & James R. Knickman with Tracy Barr PowerPoints by Robin.

Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.

1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.

Government Regulatory Agencies and Impact on Consumer Choices Presentation.

FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Safety Studies (PASS)

24-04 Excerpted from Meggs’ History of Graphic Design, Fourth Edition. Copyright 2005, All rights reserved. Published by John Wiley & Sons, Inc.

Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

CONFERENCE SERIES LLC CONFERENCES Conference Series LLC is a pioneer and leading science event organizer, which publishes around 500 open access journals.

1 Improving the agenda for SWITCH for nonprescription Medicines Sheila Kelly WSMI September 2015.

Lecture #4 Risk Assessment, philosophical approaches to risk & regulation.

iHEA 9th World Congress Sydney, July 8, 2013

Efficacy and Safety of Medicines

Track 11 Symposium 27 June :30 – 3:00 PM

Comments to the FDA on Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription Marissa Schlaifer, RPh Director of Pharmacy.

On Human Gene Editing: International Summit Statement

Interprofessional Education at the ‘MESO’ Level: The Next Frontier

Jeffrey M. Cohen, Ph.D. CIP President HRP Associates, Inc.

Prescription for Pharmaceutical Reform: Healing an Ailing System

Comments to the FDA on Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription Marissa Schlaifer, RPh Director of Pharmacy.

Minimally Invasive Compressional Assist Device

B3: Representing Service User interests in HSC

The slide shows the seven key steps that make up a systematic approach to benefit-risk assessment for medicines. Source: The CIRS Benefit-Risk Research.

Allen Chan U.S. Government Accountability Office October 2, 2018

Presentation transcript:

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. Presentation to FDA Advisory Committees July 30 th 2007 J. Rick Turner, PhD Chairman and Associate Professor, Department of Clinical Research Campbell University School of Pharmacy and President, Turner Medical Communications LLC Views expressed are those of the author and Turner Medical Communications LLC and not necessarily those of Campbell University.

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. The Benefit-risk Balance No drug is immune from possibility of unwanted responses, and a drug’s safety profile must therefore be evaluated in conjunction with its efficacy/effectiveness. Benefit-risk assessments are critical components of: Regulatory decisions affecting many patients. Clinical decisions affecting individual patients.

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. Inman and Weber (1986) “Risk-benefit judgements are complex…Irresponsible reporting by the lay press frequently leads to political pressure to restrict or ban drugs…The continued use of many valuable drugs must depend on the ability of the monitoring and regulatory agency to withstand criticism. Their policy on the whole is to warn about dangers rather than ban drugs because of them.” Inman, W.H.W. and Weber, J.C.P, 1986, The United Kingdom. In Inman, W.H.W. (Ed), Monitoring for Drug Safety, 2 nd Edition. Lancaster, UK: MTP Press/Kluwer Academic Publishers Group, p. 39. (13-47)

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. FDA Guidance for Industry: RiskMAPs (2005) “ FDA views risk management as an iterative process encompassing the assessment of risks and benefits, the minimization of risks, and the maximization of benefits.” FDA Guidance for Industry, March 2005: Development and Use of Risk Minimization Action Plans.

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. Institute of Medicine (2007) “The role of the regulator is not to impede the development of innovative medicines, but to ensure that needed drugs are available to patients and that risk-benefit information is accurate and widely available.” Institute of Medicine of the National Academies, 2007, The Future of Drug Safety: Protecting and Promoting the Health of the Public. Washington DC: The National Academies Press, p